A research team investigating the promising anti-fibrotic effects of a drug version of the hormone, relaxin, has discovered that the receptor through which it mediates its therapeutic actions can communicate and/or interact with other receptors in cells that contribute to fibrosis progression. This research may have implications for the design of clinical trials involving relaxin and its concomitant use with other drugs that act on these receptors.
